Sight Sciences Inc develops interventional medical devices for the treatment of glaucoma and dry eye disease. The company focuses on creating technologies that address the underlying physiological causes of these eye conditions. Its products enable eye care professionals to perform minimally invasive procedures that aim to preserve and restore natural eye function. Sight Sciences Inc operates primarily in the United States with additional presence in Europe.

Sight Sciences Inc generates revenue by selling its interventional devices and related accessories to health care providers. The company's main products are the OMNI Surgical System and the SION Surgical Instrument for glaucoma treatment and the TearCare system for dry eye treatment. Revenue is derived from direct sales in the United States and through distributors in select European markets. Customers include ambulatory surgery centers hospital outpatient departments and eye care practices.

The company operates through the following segments: Interventional Glaucoma and Interventional Dry Eye.

• The Interventional Glaucoma segment includes the OMNI Surgical System and the SION Surgical Instrument which are used to perform minimally invasive glaucoma surgeries that reduce intraocular pressure by targeting the drainage pathways of the eye.

• The Interventional Dry Eye segment consists of the TearCare system which delivers controlled thermal energy to melt meibomian gland obstructions and improve eyelid function in patients with evaporative dry eye disease.

Sight Sciences Inc competes in the medical device market for glaucoma and dry eye disease treatments. Its main competitors in the minimally invasive glaucoma surgery space include Glaukos Alcon AbbVie Iantrek New World Medical and Nova Eye Medical Limited. In the dry eye disease arena the company faces competition from Johnson & Johnson Alcon Abbvie and Novartis. Sight Sciences Inc differentiates itself by focusing on devices that treat the underlying physiological causes of disease and by generating strong clinical evidence to support product adoption.

The company sells its glaucoma products to ambulatory surgery centers and hospital outpatient departments where ophthalmic surgeons perform procedures. Its dry eye system is sold to optometry and ophthalmology practices that provide eye care services. Sight Sciences Inc also works with distributors in Europe to reach additional clinics and hospitals.